Alpha Tau Medical (NASDAQ:DRTS) CFO Raphi Levy Sells 2,127 Shares

Alpha Tau Medical Ltd. (NASDAQ:DRTS) CFO Raphi Levy sold 2,127 shares of the company’s stock in a transaction on Wednesday, July 1st. The stock was sold at an average price of $13.02, for a total value of $27,693.54. Following the transaction, the chief financial officer directly owned 90,180 shares in the company, valued at $1,174,143.60. This represents a 2.30% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Raphi Levy also recently made the following trade(s):

• On Tuesday, June 30th, Raphi Levy sold 20,000 shares of Alpha Tau Medical stock. The shares were sold at an average price of $12.00, for a total value of $240,000.00.
• On Thursday, June 25th, Raphi Levy sold 20,000 shares of Alpha Tau Medical stock. The stock was sold at an average price of $11.00, for a total transaction of $220,000.00.
• On Tuesday, June 23rd, Raphi Levy sold 17,500 shares of Alpha Tau Medical stock. The stock was sold at an average price of $9.55, for a total transaction of $167,125.00.
• On Wednesday, June 3rd, Raphi Levy sold 32,500 shares of Alpha Tau Medical stock. The stock was sold at an average price of $10.83, for a total transaction of $351,975.00.

Alpha Tau Medical Stock Performance

Shares of DRTS opened at $13.23 on Friday. The company has a quick ratio of 7.79, a current ratio of 7.79 and a debt-to-equity ratio of 0.09. Alpha Tau Medical Ltd. has a 52-week low of $2.87 and a 52-week high of $13.23. The company has a 50-day simple moving average of $9.75 and a 200-day simple moving average of $7.85. The company has a market capitalization of $1.20 billion, a PE ratio of -19.75 and a beta of 1.17.

Alpha Tau Medical (NASDAQ:DRTS) last released its quarterly earnings data on Monday, May 18th. The company reported ($0.26) EPS for the quarter, missing analysts’ consensus estimates of ($0.13) by ($0.13). Equities research analysts predict that Alpha Tau Medical Ltd. will post -0.67 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of research firms recently weighed in on DRTS. LADENBURG THALM/SH SH upped their price target on Alpha Tau Medical from $12.00 to $14.00 and gave the stock a “buy” rating in a report on Tuesday, May 12th. HC Wainwright reiterated a “buy” rating and set a $15.00 target price on shares of Alpha Tau Medical in a research report on Tuesday, June 2nd. Barclays boosted their target price on Alpha Tau Medical from $15.00 to $17.00 and gave the stock an “overweight” rating in a research report on Thursday, June 4th. Citigroup raised their price target on Alpha Tau Medical from $7.00 to $9.00 and gave the company a “buy” rating in a research report on Wednesday, March 11th. Finally, Piper Sandler lifted their price target on Alpha Tau Medical from $5.00 to $8.00 and gave the stock a “neutral” rating in a research note on Tuesday, May 19th. Four research analysts have rated the stock with a Buy rating, one has given a Hold rating and two have assigned a Sell rating to the company. According to MarketBeat, Alpha Tau Medical has an average rating of “Hold” and a consensus price target of $12.60.

Institutional Investors Weigh In On Alpha Tau Medical

A number of institutional investors and hedge funds have recently bought and sold shares of DRTS. Apella Capital LLC acquired a new stake in Alpha Tau Medical during the 4th quarter valued at $1,892,000. Daytona Street Capital LLC acquired a new position in shares of Alpha Tau Medical in the fourth quarter worth $749,000. Mariner LLC raised its holdings in shares of Alpha Tau Medical by 1.6% in the fourth quarter. Mariner LLC now owns 125,165 shares of the company’s stock worth $620,000 after acquiring an additional 1,915 shares during the last quarter. Millennium Management LLC boosted its stake in shares of Alpha Tau Medical by 185.7% during the fourth quarter. Millennium Management LLC now owns 107,815 shares of the company’s stock valued at $534,000 after acquiring an additional 70,081 shares during the last quarter. Finally, Renaissance Technologies LLC acquired a new stake in shares of Alpha Tau Medical during the first quarter valued at $286,000. Hedge funds and other institutional investors own 2.65% of the company’s stock.

Alpha Tau Medical Company Profile

Alpha Tau Medical Ltd. is a medical technology company headquartered in Ness Ziona, Israel, focused on developing targeted alpha-radiation therapies for the treatment of solid tumors. The company’s core innovation, known as Diffusing Alpha-emitters Radiation Therapy (DaRT), employs short-lived radioactive isotopes to deliver high-energy alpha particles directly within or adjacent to tumor tissues. By harnessing the potent cytotoxic effects of alpha radiation, Alpha Tau Medical aims to offer a novel approach to brachytherapy that can potentially overcome radioresistance and spare surrounding healthy tissue.

The company’s lead product, Alpha DaRT, is currently being evaluated in clinical studies for a range of indications including recurrent or metastatic head and neck cancers, skin cancers, and other solid tumors.